Yüklüyor......
What Path Do We Take?
As existing biologics gain indications and new drugs make it to market, the array of choices makes it challenging to pick the right treatment for a given patient. Clinical effectiveness is the most important factor, but at the policy level, cost has to enter the discussion. Where?
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioCommunications LLC
2008
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2706158/ https://ncbi.nlm.nih.gov/pubmed/22478710 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|